CFO
UTHR icon

CVA Family Office’s United Therapeutics UTHR Stock Holding History

CVA Family Office’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.7K Buy
+67
New +$33.4K ﹤0.01% 652
2025
Q3 		– Sell
-2
Closed -$575 – 1348
2025
Q2 		$575 Hold
2
– – ﹤0.01% 1194
2025
Q1 		$617 Buy
+2
New +$685 ﹤0.01% 1186

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

CVA Family Office's UTHR Position: Q1 2026 in Review

CVA Family Office opened a new position in United Therapeutics (UTHR) in Q1 2026: 67 shares worth $39.7K. The stake represents ﹤0.01% of the portfolio and ranks #652 among its holdings. This is a return to the name: CVA Family Office previously reported a position in UTHR as recently as Q2 2025.

CVA Family Office first reported a position in UTHR in Q1 2025 and has held it in 3 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • CVA Family Office held 67 shares of United Therapeutics worth $39.7K as of Q1 2026.
  • United Therapeutics was a new CVA Family Office position in Q1 2026.
  • United Therapeutics made up ﹤0.01% of CVA Family Office's portfolio in Q1 2026, its #652 holding.
  • CVA Family Office first reported a position in United Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on CVA Family Office's 13F filing for Q1 2026, filed 29 Apr 2026.